Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Resilience Ratio

Latest as of March 2026: 1.58%

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has an Asset Resilience Ratio of 1.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥60.00 Million

≈ $8.78 Million USD Cash + Short-term Investments

Total Assets

CN¥3.80 Billion

≈ $556.41 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2025)

This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 301096 asset base.

Liquid Assets Composition Over Time

This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Hangzhou Bio-Sincerity Pharma-Tech Co.Lt total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥60.00 Million	1.58%
Total Liquid Assets	CN¥60.00 Million	1.58%

Asset Resilience Insights

Limited Liquidity: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. maintains only 1.58% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Industry Peers by Asset Resilience Ratio

Compare Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Pfizer Inc NYSE:PFE	Drug Manufacturers - General	5.33%
AbbVie Inc NYSE:ABBV	Drug Manufacturers - General	0.02%
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	0.22%
AstraZeneca PLC MX:AZNN	Drug Manufacturers - General	0.03%
Novartis AG ADR NYSE:NVS	Drug Manufacturers - General	0.06%
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd SHE:300357	Drug Manufacturers - General	9.91%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%
Eli Lilly and Company SA:LILY34	Drug Manufacturers - General	6.46%

Annual Asset Resilience Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2024–2025)

The table below shows the annual Asset Resilience Ratio data for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.17%	CN¥80.00 Million ≈ $11.71 Million	CN¥3.69 Billion ≈ $539.42 Million	-0.06pp
2024-12-31	2.23%	CN¥83.00 Million ≈ $12.15 Million	CN¥3.72 Billion ≈ $544.53 Million	--

pp = percentage points

About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

SHE:301096 China Drug Manufacturers - General

Market Cap

$842.01 Million

CN¥5.75 Billion CNY

Market Cap Rank

#9750 Global

#2524 in China

Share Price

CN¥52.68

Change (1 day)

+4.63%

52-Week Range

CN¥35.96 - CN¥68.99

All Time High

CN¥98.58